Regeneron registers Phase 1 REGN17235 trial and joins Maryland-led lung cancer study

This week brought two newly registered trials touching Regeneron programs, both not yet recruiting.

• Regeneron registered a Phase 1 study of REGN17235 for adults with Clonal Cytopenia of Undetermined Significance (CCUS) and low-risk myelodysplastic syndrome carrying the SF3B1 mutation. The trial is testing what dose of the study drug best treats CCUS and LR-MDS¹, with an estimated enrollment of 52 participants¹ and primary completion estimated for 2031-05-05.
• The University of Maryland, Baltimore is sponsoring a Phase 2 pilot trial called "Chemo-PHREE," with Regeneron listed as a collaborator. The study will test whether cemiplimab is safe in adult patients with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer, using a novel adaptive treatment strategy in patients with PD-L1 ≥50%², enrolling an estimated 30 participants².